



anteo diagnostics

4 August 2016
Company Announcements Office
Australian Securities Exchange Limited
Level 6, 20 Bridge Street Sydney NSW 2000

ANTEO DIAGNOSTICS
Notice under section 708A(5)(e) of the Corporations Act 2001(Cth)

This notice is given by Anteo Diagnostics Ltd (ABN 75 070 028 625) (**Anteo**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the **Act**) as modified by ASIC Class Order 08/35 (**CO 08/35**).

On 3 August 2016, Anteo Diagnostics Limited ("the Company") issued 5,777,457 fully paid ordinary shares in accordance with the terms of its convertible securities issued pursuant to the convertible securities subscription agreement with Bergen Global Opportunity Fund, LP, which was announced to the market on 3 March 2016.

Anteo advises that:

1. The shares were issued without disclosure to investors under Part 6D.2 of the Act as modified by CO 08/35.
2. This Notice is being given under section 708A(5)(e) of the Act as modified by CO 08/35.
3. As at the date of this notice, Anteo has complied with:
 - (a) The provisions of Chapter 2M of the Act as they apply to Anteo; and
 - (b) Section 674 of the Act; and
4. As at the date of this notice, there is no information that is "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Act which is required to be disclosed by Anteo.